Miodrag Sreckovic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Miodrag Sreckovic has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
Vladimir Miloradovic
Clinical Center of Kragujevac, Cardiology Clinic, Department of Interventional Cardiology, Kragujevac
9 shared publicationsDusan Nikolic
Clinical Center of Kragujevac, Cardiology Clinic, Department of Interventional Cardiology, Kragujevac
6 shared publicationsNikola Jagic
Department of Radiology, Faculty of Medical Sciences, University of Kragujevac, Serbia
6 shared publicationsMladen Tasic
5 shared publications- Dragica Selakovic
Department of Physiology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
4 shared publications - Gvozden Rosic
Department of Physiology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
4 shared publications
Latest Publications
- Open Access
- 23 June 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (7) , 661
Genetic Assessment of Neurotoxicity Accompanied by Inhalational Anesthesia in Preclinical Studies with Focus on Sevoflurane and Isoflurane—A Narrative Review
Inhalational anesthesia, which includes anesthetics such as sevoflurane, isoflurane, and desflurane, is widely used in clinical settings for surgical interventions across all age groups. Nonetheless, recent findings from preclinical research raise important questions regarding their potential neurotoxic effects, especially within the developing brain, though clinical implications remain to be fully established. This narrative review was conducted through a literature search of the PubMed database and synthesizes preclinical investigations into gene modifications associated with neurotoxicity following exposure to inhalation anesthetics. Emphasis was placed on anesthetic exposure in human and animal-derived cell lines, neurodevelopmental animal models, as well as adult and aged animals. In various models, the neurotoxic mechanisms of inhalational anesthesia involve a complex interaction of apoptosis, oxidative stress, mitochondrial dysfunction, neuroinflammation, and epigenetic remodeling. Developmental studies indicate additional susceptibilities, including impaired neuronal migration, myelination deficits, and transgenerational epigenetic effects, whereas aging models exhibit oxidative stress injury, microglial activation, and heightened perioperative neurocognitive sensitivity. Understanding these neurotoxic mechanisms is essential for identifying risk factors, formulating age-specific neuroprotective strategies, and enhancing the overall safety of anesthetic use, particularly in vulnerable populations.
- 23 June 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (7) , 661
Open AccessGenetic Assessment of Neurotoxicity Accompanied by Inhalational Anesthesia in Preclinical Studies with Focus on Sevoflurane and Isoflurane—A Narrative Review
Inhalational anesthesia, which includes anesthetics such as sevoflurane, isoflurane, and desflurane, is widely used in clinical settings for surgical interventions across all age groups. Nonetheless, recent findings from preclinical research raise important questions regarding their potential neurotoxic effects, especially within the developing brain, though clinical implications remain to be fully established. This narrative review was conducted through a literature search of the PubMed database and synthesizes preclinical investigations into gene modifications associated with neurotoxicity following exposure to inhalation anesthetics. Emphasis was placed on anesthetic exposure in human and animal-derived cell lines, neurodevelopmental animal models, as well as adult and aged animals. In various models, the neurotoxic mechanisms of inhalational anesthesia involve a complex interaction of apoptosis, oxidative stress, mitochondrial dysfunction, neuroinflammation, and epigenetic remodeling. Developmental studies indicate additional susceptibilities, including impaired neuronal migration, myelination deficits, and transgenerational epigenetic effects, whereas aging models exhibit oxidative stress injury, microglial activation, and heightened perioperative neurocognitive sensitivity. Understanding these neurotoxic mechanisms is essential for identifying risk factors, formulating age-specific neuroprotective strategies, and enhancing the overall safety of anesthetic use, particularly in vulnerable populations.
- Open Access
- 23 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (9) , 3742
Neurotrophins and Galectin-3: Hidden Keys in Neuroinflammation—A Narrative Review
Galectin-3 (Gal-3) is a multifunctional molecule that exerts pleiotropic effects in inflammatory responses and contributes to the pathogenesis of numerous immune-mediated diseases. Although Gal-3 has been known for more than five decades, it remains a lectin with intriguing and not yet fully elucidated properties. The existing body of evidence underscores the importance of Gal-3 in the regulation of homeostatic and inflammatory processes. Neurotrophins are traditionally recognized as key regulators of neuronal development, survival, and synaptic plasticity; nevertheless, accumulating evidence indicates that they also play important roles in immune regulation and neuroimmune communication. Importantly, neurotrophins are also produced by immune cells, including monocytes, macrophages, lymphocytes, and basophils, which express functional neurotrophin receptors including tropomyosin receptor kinase A (TrkA), tropomyosin receptor kinase A (TrkB), and p75 neurotrophin receptor (p75NTR). In this narrative review, we synthesize current evidence on neuroinflammation, neurotrophins, and Gal-3, with a particular focus on the molecular mechanisms involved in the crosstalk between neurotrophins and Gal-3 or immune cells. We further examine how this neuroimmune–neurotrophic crosstalk contributes to the pathogenesis of psychiatric and neurodegenerative disorders, as well as other neurological conditions. Finally, we discuss the emerging therapeutic potential of targeting neurotrophins and Gal-3 as modulators of neuroinflammation.
- 23 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (9) , 3742
Open AccessNeurotrophins and Galectin-3: Hidden Keys in Neuroinflammation—A Narrative Review
Galectin-3 (Gal-3) is a multifunctional molecule that exerts pleiotropic effects in inflammatory responses and contributes to the pathogenesis of numerous immune-mediated diseases. Although Gal-3 has been known for more than five decades, it remains a lectin with intriguing and not yet fully elucidated properties. The existing body of evidence underscores the importance of Gal-3 in the regulation of homeostatic and inflammatory processes. Neurotrophins are traditionally recognized as key regulators of neuronal development, survival, and synaptic plasticity; nevertheless, accumulating evidence indicates that they also play important roles in immune regulation and neuroimmune communication. Importantly, neurotrophins are also produced by immune cells, including monocytes, macrophages, lymphocytes, and basophils, which express functional neurotrophin receptors including tropomyosin receptor kinase A (TrkA), tropomyosin receptor kinase A (TrkB), and p75 neurotrophin receptor (p75NTR). In this narrative review, we synthesize current evidence on neuroinflammation, neurotrophins, and Gal-3, with a particular focus on the molecular mechanisms involved in the crosstalk between neurotrophins and Gal-3 or immune cells. We further examine how this neuroimmune–neurotrophic crosstalk contributes to the pathogenesis of psychiatric and neurodegenerative disorders, as well as other neurological conditions. Finally, we discuss the emerging therapeutic potential of targeting neurotrophins and Gal-3 as modulators of neuroinflammation.
- Open Access
- 20 March 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (6) , 2817
Neurotrophin System Alterations Associated with Neurotoxicity Accompanied by Carotid Artery Diseases—A Systematic Review
According to neuropsychiatric sequelae for cardiovascular pathology, carotid artery disease (CAD) represents a significant medical, social, and economic burden. Numerous efforts have been made to define reliable markers that can reflect the principal pathological event and the effect of employed therapeutic protocols, prognoses, and clinical outcomes of CAD. However, the potential role of the neurotrophin (NT) system has not yet been confirmed. This narrative review was conducted following a literature search of PubMed, which included all studies on NT system elements and CAD published over the last two decades, encompassing both animal and clinical investigations, regarding the potential use of NT system elements as biomarkers for neurotoxicity manifestations and therapeutic effectiveness in CAD. Still, the analysis presented in this review is not sufficient to reveal whether NT system elements can be considered as exploratory or standard biomarkers for the evaluation of CAD. Further research is essential to elucidate this dilemma.
- 20 March 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (6) , 2817
Open AccessNeurotrophin System Alterations Associated with Neurotoxicity Accompanied by Carotid Artery Diseases—A Systematic Review
According to neuropsychiatric sequelae for cardiovascular pathology, carotid artery disease (CAD) represents a significant medical, social, and economic burden. Numerous efforts have been made to define reliable markers that can reflect the principal pathological event and the effect of employed therapeutic protocols, prognoses, and clinical outcomes of CAD. However, the potential role of the neurotrophin (NT) system has not yet been confirmed. This narrative review was conducted following a literature search of PubMed, which included all studies on NT system elements and CAD published over the last two decades, encompassing both animal and clinical investigations, regarding the potential use of NT system elements as biomarkers for neurotoxicity manifestations and therapeutic effectiveness in CAD. Still, the analysis presented in this review is not sufficient to reveal whether NT system elements can be considered as exploratory or standard biomarkers for the evaluation of CAD. Further research is essential to elucidate this dilemma.
- 1 January 2025
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Medicinski casopis
- Vol. 59 (3) , 109-116
The role of neurotrophins in acute coronary syndrome: Prognostic and diagnostic value of new biomarkers
Acute coronary syndrome (ACS) remains the leading cause of morbidity and mortality worldwide. While existing diagnostic and prognostic biomarkers have improved patient care, there is still a need for newer, more specific markers to enable more precise risk stratification and individualized treatment. Neurotrophins are a family of proteins essential for neuronal survival and function. In recent years, their role in cardiovascular diseases has become increasingly recognized. The aim of this review is to present current knowledge on the role of neurotrophins, primarily brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), in the pathophysiology of ACS, and to evaluate their potential as novel diagnostic and prognostic biomarkers. The studies analyzed indicate significant changes in neurotrophin levels during ACS, linking them to ischemia, reperfusion injury, inflammation, and myocardial remodeling. There is evidence that elevated or decreased levels of certain neurotrophins can predict short-term and long-term outcomes in patients with ACS. Further research, especially large multicenter studies, is necessary to confirm the value of neurotrophin measurement in ACS as a significant biomarker in clinical practice.
- 1 January 2025
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Medicinski casopis
- Vol. 59 (3) , 109-116
The role of neurotrophins in acute coronary syndrome: Prognostic and diagnostic value of new biomarkers
Acute coronary syndrome (ACS) remains the leading cause of morbidity and mortality worldwide. While existing diagnostic and prognostic biomarkers have improved patient care, there is still a need for newer, more specific markers to enable more precise risk stratification and individualized treatment. Neurotrophins are a family of proteins essential for neuronal survival and function. In recent years, their role in cardiovascular diseases has become increasingly recognized. The aim of this review is to present current knowledge on the role of neurotrophins, primarily brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), in the pathophysiology of ACS, and to evaluate their potential as novel diagnostic and prognostic biomarkers. The studies analyzed indicate significant changes in neurotrophin levels during ACS, linking them to ischemia, reperfusion injury, inflammation, and myocardial remodeling. There is evidence that elevated or decreased levels of certain neurotrophins can predict short-term and long-term outcomes in patients with ACS. Further research, especially large multicenter studies, is necessary to confirm the value of neurotrophin measurement in ACS as a significant biomarker in clinical practice.
- Open Access
- 1 December 2024
- Published by University of Nis Faculty of Medicine in AFMN Biomedicine
- Vol. 42 (2) , 207-218
N-terminal pro-brain natriuretic peptide superiority for prognosis of major adverse cardiovascular events in patients with acute myocardial infarction without heart failure
Many markers are used to evaluate the prognosis in patients with acute myocardial infarction (AMI). Researches are focused on available markers with high sensitivity and specificity. The aim of our study was to evaluate the prognostic value of N-terminal pro brain natriuretic peptide (NT-proBNP) and its superiority compared with other prognostic markers in patients with AMI. Sixty-six patients with the diagnosis of AMI were enrolled in the study. The evaluated variables were: symptoms, cardiovascular risk factors, laboratory analyses (including NT-proBNP), GRACE risk score, electrocardiography, left ventricular ejection fraction (LVEF) and coronary angiography. One and six-month major adverse cardiovascular events (MACE) included: reAMI, heart rhythm disorders, acute heart failure, stroke, fatal event. Patients with one-month and six-month MACE were older, had anterior AMI, higher levels of NT-proBNP, urea, creatinine, lower LVEF, creatinine clearance (CCr) and hemoglobin level. NT-proBNP is an independent predictor of short-term (p = 0.002) and long-term (p = 0.000) prognosis. Its cut point of 1,467 pg/ml is a significant independent predictor of one-month MACE and cut point of 996 pg/ml is a significant independent predictor of six-month MACE. NT-proBNP is a strong short-term and long-term predictive marker in AMI patients without heart failure.
- 1 December 2024
- Published by University of Nis Faculty of Medicine in AFMN Biomedicine
- Vol. 42 (2) , 207-218
Open AccessN-terminal pro-brain natriuretic peptide superiority for prognosis of major adverse cardiovascular events in patients with acute myocardial infarction without heart failure
Many markers are used to evaluate the prognosis in patients with acute myocardial infarction (AMI). Researches are focused on available markers with high sensitivity and specificity. The aim of our study was to evaluate the prognostic value of N-terminal pro brain natriuretic peptide (NT-proBNP) and its superiority compared with other prognostic markers in patients with AMI. Sixty-six patients with the diagnosis of AMI were enrolled in the study. The evaluated variables were: symptoms, cardiovascular risk factors, laboratory analyses (including NT-proBNP), GRACE risk score, electrocardiography, left ventricular ejection fraction (LVEF) and coronary angiography. One and six-month major adverse cardiovascular events (MACE) included: reAMI, heart rhythm disorders, acute heart failure, stroke, fatal event. Patients with one-month and six-month MACE were older, had anterior AMI, higher levels of NT-proBNP, urea, creatinine, lower LVEF, creatinine clearance (CCr) and hemoglobin level. NT-proBNP is an independent predictor of short-term (p = 0.002) and long-term (p = 0.000) prognosis. Its cut point of 1,467 pg/ml is a significant independent predictor of one-month MACE and cut point of 996 pg/ml is a significant independent predictor of six-month MACE. NT-proBNP is a strong short-term and long-term predictive marker in AMI patients without heart failure.
- Open Access
Time Is Life: Golden Ten Minutes on Scene–EuReCa_Serbia 2014–2023
Background and Objectives: This study analyzed the frequency of factors influencing the course and outcomes of out-of-hospital cardiac arrest (OHCA) in Serbia and the prediction of pre-hospital outcomes and survival. Materials and Methods: Data were collected during the period from 1 October 2014, to 31 September 2023, according to the protocol of the EuReCa_One study (clinical trial ID number NCT02236819). Results: Overall 9303 OHCA events were registered with a median age of 71 (IQR 61–81) years and 59.7% of them being males. The annual OHCA incidence was 85.60 ± 20.73/100,000. Within all bystander-witnessed cases, bystander-initiated cardiopulmonary resuscitation in 15.3%. Within the resuscitation-initiated group, return-of-spontaneous circulation (ROSC) on scene (any ROSC) was present in 1037/4053 cases (25.6%) and ROSC on admission to the nearest hospital in 792/4053 cases (19.5%), while 201/4053 patients survived to hospital discharge (5.0%). Predictive potential on pre-hospital outcomes was shown by several factors. Also, of all patients having any ROSC, 89.2% were admitted to the hospital alive. The probability of any ROSC dropped below 50% after 17 min passed after the emergency call and 10 min after the EMS scene arrival. These time intervals were significantly associated with survival to hospital discharge (p < 0.001). Five-minute time intervals between both emergency calls and any ROSC and EMS scene arrival and any ROSC also had a significant predictive potential for survival to hospital discharge (p < 0.001, HR 1.573, 95% CI 1.303–1.899 and p = 0.017, HR 1.184, 95% CI 1.030–1.361, respectively). Conclusions: A 10-min time on scene to any ROSC is a crucial time-related factor for achieving any ROSC, and indirectly admission ROSC and survival to hospital discharge, and represents a golden time interval spent on scene in the management of OHCA patients. A similar effect has a time interval of 17 min from an emergency call. Further investigations should be focused on factors influencing these time intervals, especially time spent on scene.
Open AccessTime Is Life: Golden Ten Minutes on Scene–EuReCa_Serbia 2014–2023
Background and Objectives: This study analyzed the frequency of factors influencing the course and outcomes of out-of-hospital cardiac arrest (OHCA) in Serbia and the prediction of pre-hospital outcomes and survival. Materials and Methods: Data were collected during the period from 1 October 2014, to 31 September 2023, according to the protocol of the EuReCa_One study (clinical trial ID number NCT02236819). Results: Overall 9303 OHCA events were registered with a median age of 71 (IQR 61–81) years and 59.7% of them being males. The annual OHCA incidence was 85.60 ± 20.73/100,000. Within all bystander-witnessed cases, bystander-initiated cardiopulmonary resuscitation in 15.3%. Within the resuscitation-initiated group, return-of-spontaneous circulation (ROSC) on scene (any ROSC) was present in 1037/4053 cases (25.6%) and ROSC on admission to the nearest hospital in 792/4053 cases (19.5%), while 201/4053 patients survived to hospital discharge (5.0%). Predictive potential on pre-hospital outcomes was shown by several factors. Also, of all patients having any ROSC, 89.2% were admitted to the hospital alive. The probability of any ROSC dropped below 50% after 17 min passed after the emergency call and 10 min after the EMS scene arrival. These time intervals were significantly associated with survival to hospital discharge (p < 0.001). Five-minute time intervals between both emergency calls and any ROSC and EMS scene arrival and any ROSC also had a significant predictive potential for survival to hospital discharge (p < 0.001, HR 1.573, 95% CI 1.303–1.899 and p = 0.017, HR 1.184, 95% CI 1.030–1.361, respectively). Conclusions: A 10-min time on scene to any ROSC is a crucial time-related factor for achieving any ROSC, and indirectly admission ROSC and survival to hospital discharge, and represents a golden time interval spent on scene in the management of OHCA patients. A similar effect has a time interval of 17 min from an emergency call. Further investigations should be focused on factors influencing these time intervals, especially time spent on scene.
- Open Access
- 31 October 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (21) , 3348
Galectin-3 as a Prognostic Biomarker in Patients with First Acute Myocardial Infarction without Heart Failure
Background: Galectin-3 (Gal-3) is a biomarker involved in a wide range of diseases including cardiac remodeling following acute myocardial infarction (AMI). Identification of prognostic markers in patients with AMI can guide strategies towards improved survival and quality of life. Methods: Our study included 59 patients with AMI and a preserved ejection fraction. We determined the Gal-3 plasma concentration within 24 h of chest pain onset from the aortic root, femoral/radial artery, coronary sinus and cubital vein. Major adverse cardiovascular events (MACEs) were evaluated at six months follow-up. Results: MACE at six months post-AMI was recorded in 20 patients (34%). The Gal-3 plasma concentration from the aortic root and the femoral/radial artery were independent predictors of MACE at six months follow-up after the first AMI (OR 1.228; 95%CI: 1.011–1.491; p = 0.038; OR 3.438; 95%CI: 1.275–9.265; p = 0.015). ROC analysis identifies the Gal-3 plasma concentration from the aortic root as a better predictor of MACE or death (cut-off ≥ 10.86 ng/mL; AUC 0.858; 95%CI: 0.744–0.973; p < 0.001) than Gal-3 plasma concentration from the femoral/radial artery (cut-off ≥ 10.18 ng/mL; AUC 0.742; 95%CI: 0.596–0.888; p = 0.006). Conclusion: the Gal-3 plasma concentration in patients with AMI determined during coronary angiography, especially from the aortic root, within 24 h after chest pain onset is a valuable biomarker of prognosis at six months follow-up.
- 31 October 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (21) , 3348
Open AccessGalectin-3 as a Prognostic Biomarker in Patients with First Acute Myocardial Infarction without Heart Failure
Background: Galectin-3 (Gal-3) is a biomarker involved in a wide range of diseases including cardiac remodeling following acute myocardial infarction (AMI). Identification of prognostic markers in patients with AMI can guide strategies towards improved survival and quality of life. Methods: Our study included 59 patients with AMI and a preserved ejection fraction. We determined the Gal-3 plasma concentration within 24 h of chest pain onset from the aortic root, femoral/radial artery, coronary sinus and cubital vein. Major adverse cardiovascular events (MACEs) were evaluated at six months follow-up. Results: MACE at six months post-AMI was recorded in 20 patients (34%). The Gal-3 plasma concentration from the aortic root and the femoral/radial artery were independent predictors of MACE at six months follow-up after the first AMI (OR 1.228; 95%CI: 1.011–1.491; p = 0.038; OR 3.438; 95%CI: 1.275–9.265; p = 0.015). ROC analysis identifies the Gal-3 plasma concentration from the aortic root as a better predictor of MACE or death (cut-off ≥ 10.86 ng/mL; AUC 0.858; 95%CI: 0.744–0.973; p < 0.001) than Gal-3 plasma concentration from the femoral/radial artery (cut-off ≥ 10.18 ng/mL; AUC 0.742; 95%CI: 0.596–0.888; p = 0.006). Conclusion: the Gal-3 plasma concentration in patients with AMI determined during coronary angiography, especially from the aortic root, within 24 h after chest pain onset is a valuable biomarker of prognosis at six months follow-up.
- Open Access
- 25 September 2023
- Published by MDPI AG in Preprints.org
Galectin-3 as a Prognostic Biomarker in Patients with First Acute Myocardial Infarction Without Heart Failure
Background: Galectin-3 (Gal-3) is a biomarker involved in a wide range of diseases including cardiac remodeling following acute myocardial infarction (AMI). Identification of prognostic markers in patients with AMI can guide strategies towards improved survival and the quality of life. Methods: Our study included 59 patients with AMI and preserved ejection fraction. We determined the Gal-3 plasma concentration within 24 hours of chest pain onset from aortic root, femoral/radial artery, coronary sinus and cubital vein. Major adverse cardiovascular events (MACE) were evaluated at six months follow-up. Results: MACE at six months post-AMI was recorded in 20 patients (34%). The Gal-3 plasma concentration from aortic root and the femoral/radial artery were independent predictors of MACE at six months follow-up after the first AMI (OR 1.228; 95%CI: 1.011-1.491; p=0.038; OR 3.438; 95%CI: 1.275-9.265; p=0.015). ROC analysis identifies the Gal-3 plasma concentration from aortic root as a better predictor of MACE or death (cut-off >10.86 ng/ml; AUC 0.858; 95%CI: 0.744-0.973; p10.18 ng/ml; AUC 0.742; 95%CI: 0.596-0.888; p=0.006). Conclusion: The Gal-3 plasma concentration in patients with AMI determined during coronary angiography, especially from the aortic root, within 24 hours after chest pain onset is a valuable biomarker of prognosis at six months follow-up.
- 25 September 2023
- Published by MDPI AG in Preprints.org
Open AccessGalectin-3 as a Prognostic Biomarker in Patients with First Acute Myocardial Infarction Without Heart Failure
Background: Galectin-3 (Gal-3) is a biomarker involved in a wide range of diseases including cardiac remodeling following acute myocardial infarction (AMI). Identification of prognostic markers in patients with AMI can guide strategies towards improved survival and the quality of life. Methods: Our study included 59 patients with AMI and preserved ejection fraction. We determined the Gal-3 plasma concentration within 24 hours of chest pain onset from aortic root, femoral/radial artery, coronary sinus and cubital vein. Major adverse cardiovascular events (MACE) were evaluated at six months follow-up. Results: MACE at six months post-AMI was recorded in 20 patients (34%). The Gal-3 plasma concentration from aortic root and the femoral/radial artery were independent predictors of MACE at six months follow-up after the first AMI (OR 1.228; 95%CI: 1.011-1.491; p=0.038; OR 3.438; 95%CI: 1.275-9.265; p=0.015). ROC analysis identifies the Gal-3 plasma concentration from aortic root as a better predictor of MACE or death (cut-off >10.86 ng/ml; AUC 0.858; 95%CI: 0.744-0.973; p10.18 ng/ml; AUC 0.742; 95%CI: 0.596-0.888; p=0.006). Conclusion: The Gal-3 plasma concentration in patients with AMI determined during coronary angiography, especially from the aortic root, within 24 hours after chest pain onset is a valuable biomarker of prognosis at six months follow-up.
- Open Access
- 13 September 2023
- Published by Walter de Gruyter GmbH in Experimental and Applied Biomedical Research (EABR)
- Vol. {"content-
Nt-Probnp in Patients with Acute Myocardial Infarction Without Heart Failure
NT-proBNP is marker of acute heart failure. Recent investigation implicate its role in different cardiac and non-cardiac diseases and different mechanism of release in patients with STEMI and NSTEMI. Our study included 66 patients with diagnosis of acute myocardial infarction, hospitalized in Clinical Centre Kragujevac. We evaluated standard biochemical analysis including NTproBNP, electrocardiography, transthoracic echocardiography and coronary angiography. The most common cardiovascular risk factors were emotional stress (93,94%), and physical inactivity( 81,82%). NT-proBNP values were higher in patients with AMI vs health volunteers (943 vs. 162,5 pg/ml, p = 0,0001), NSTEMI vs STEMI patients (1427 pg/ml vs. 592 pg/m, p = 0,005), patients with culprit lesion on left vs right coronary artery (1421 vs. 548, p =0.02), and anterior vs inferior location AMI (1714vs. 625, p =0.022). We found positive correlation NT-proBNP values with CRP, urea, creatinine, and negative correlation with triglicerides, hemoglobin, left ventricular ejection fraction. Higher values of NT-proBNP values are recorded in patients with AMI, NSTEMI, anterior location AMI and with culprit lesion on left coronary artery.
- 13 September 2023
- Published by Walter de Gruyter GmbH in Experimental and Applied Biomedical Research (EABR)
- Vol. {"content-
Open AccessNt-Probnp in Patients with Acute Myocardial Infarction Without Heart Failure
NT-proBNP is marker of acute heart failure. Recent investigation implicate its role in different cardiac and non-cardiac diseases and different mechanism of release in patients with STEMI and NSTEMI. Our study included 66 patients with diagnosis of acute myocardial infarction, hospitalized in Clinical Centre Kragujevac. We evaluated standard biochemical analysis including NTproBNP, electrocardiography, transthoracic echocardiography and coronary angiography. The most common cardiovascular risk factors were emotional stress (93,94%), and physical inactivity( 81,82%). NT-proBNP values were higher in patients with AMI vs health volunteers (943 vs. 162,5 pg/ml, p = 0,0001), NSTEMI vs STEMI patients (1427 pg/ml vs. 592 pg/m, p = 0,005), patients with culprit lesion on left vs right coronary artery (1421 vs. 548, p =0.02), and anterior vs inferior location AMI (1714vs. 625, p =0.022). We found positive correlation NT-proBNP values with CRP, urea, creatinine, and negative correlation with triglicerides, hemoglobin, left ventricular ejection fraction. Higher values of NT-proBNP values are recorded in patients with AMI, NSTEMI, anterior location AMI and with culprit lesion on left coronary artery.
- Open Access
- 1 March 2018
- Published by Walter de Gruyter GmbH in Serbian Journal of Experimental and Clinical Research
- Vol. 19 (1) , 73-80
Cardiorenal Syndrome Type 1: Definition, Etiopathogenesis, Diagnostics and Treatment
Cardiorenal Syndrome Type 1 (CRS-1) is defined as an acute worsening of heart function leading to acute kidney injury and/or dysfunction. It is an important cause of hospitalization which affects the diagnosis as well as the prognosis and treatment of patients. The purpose of this paper is to analyze causes that lead to the development of cardiorenal syndrome type 1 and its clinical consequences, as well as to emphasize the clinical importance of its early detection. The clinical studies and professional papers dealing with etiopathogenesis, diagnosis and treatment of cardiorenal syndrome type 1, have been analyzed. The most important role in the occurrence of cardio renal syndrome type 1 is played by hemodynamic mechanisms, activation of neurohumoral systems, inflammation and imbalance between the production of reactive oxygen species (ROS) and nitric oxide (NO). Diagnosis of cardiorenal syndrome type 1 involves biomarkers of acute renal injury among which the most important are: neutrophil gelatinaseassociated lipocalin (NGAL), cystatin C, kidney injury molecule 1 (KIM-1), liver-type fatty acid binding protein (L-FABP), IL-18 and the values of nitrogen compounds in serum. In addition to a pharmacological therapy, various modalities of extracorporeal ultrafiltration are applied in treatment of CRS-1, particularly if there is resistance to the use of diuretic therapy. As opposed to the experimental models, in clinical practice acute renal injury is often diagnosed late so that the measures taken do not give the expected results and the protective role shown in experimental conditions do not give the same results. For all these reasons, it is necessary to analyze the pathophysiology of renal impairment in cardiorenal syndrome as well as detect early indicators of kidney injury that could have clinical benefit and positive impact on reducing the cost of treatment.
- 1 March 2018
- Published by Walter de Gruyter GmbH in Serbian Journal of Experimental and Clinical Research
- Vol. 19 (1) , 73-80
Open AccessCardiorenal Syndrome Type 1: Definition, Etiopathogenesis, Diagnostics and Treatment
Cardiorenal Syndrome Type 1 (CRS-1) is defined as an acute worsening of heart function leading to acute kidney injury and/or dysfunction. It is an important cause of hospitalization which affects the diagnosis as well as the prognosis and treatment of patients. The purpose of this paper is to analyze causes that lead to the development of cardiorenal syndrome type 1 and its clinical consequences, as well as to emphasize the clinical importance of its early detection. The clinical studies and professional papers dealing with etiopathogenesis, diagnosis and treatment of cardiorenal syndrome type 1, have been analyzed. The most important role in the occurrence of cardio renal syndrome type 1 is played by hemodynamic mechanisms, activation of neurohumoral systems, inflammation and imbalance between the production of reactive oxygen species (ROS) and nitric oxide (NO). Diagnosis of cardiorenal syndrome type 1 involves biomarkers of acute renal injury among which the most important are: neutrophil gelatinaseassociated lipocalin (NGAL), cystatin C, kidney injury molecule 1 (KIM-1), liver-type fatty acid binding protein (L-FABP), IL-18 and the values of nitrogen compounds in serum. In addition to a pharmacological therapy, various modalities of extracorporeal ultrafiltration are applied in treatment of CRS-1, particularly if there is resistance to the use of diuretic therapy. As opposed to the experimental models, in clinical practice acute renal injury is often diagnosed late so that the measures taken do not give the expected results and the protective role shown in experimental conditions do not give the same results. For all these reasons, it is necessary to analyze the pathophysiology of renal impairment in cardiorenal syndrome as well as detect early indicators of kidney injury that could have clinical benefit and positive impact on reducing the cost of treatment.